Società | Nome | Borsa | Settore | Industria | Capitalizzazione di mercato | Rapporto Prezzo/Utile | Rapporto PEG | Ultimo prezzo di scambio | Variazione giornaliera (%) | Fair Value | Rialzo Fair Value | Etichetta Fair Value | Price Target (analisti) | Rialzo target analisti | Salute complessiva |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Eli Lilly and Co | Buenos Aires | Salute | Prodotti farmaceutici | 809,02 Bln ARS | 112,4x | 8,72 | 19.600 ARS | 0,1% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Johnson & Johnson DRC | Buenos Aires | Salute | Prodotti farmaceutici | 389,03 Bln ARS | 27x | 0,11 | 13.150 ARS | 0,4% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Johnson Johnson DRC | Buenos Aires | Salute | Prodotti farmaceutici | 389,03 Bln ARS | 27x | 1.600 ARS | 0% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | |||
Johnson & Johnson | Buenos Aires | Salute | Prodotti farmaceutici | 378,84 Bln ARS | 10,4x | 0,31 | 815 ARS | 0% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Abbvie | Buenos Aires | Salute | Prodotti farmaceutici | 327,86 Bln ARS | 62,8x | -1,68 | 22.550 ARS | 0,4% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Merck & Co DRC | Buenos Aires | Salute | Prodotti farmaceutici | 270,92 Bln ARS | 20,1x | 0,06 | 25.975 ARS | -0,8% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
AstraZeneca PLC | Buenos Aires | Salute | Prodotti farmaceutici | 236,66 Bln ARS | 37,4x | 8,67 | 46.650 ARS | 0,4% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Novartis DRC | Buenos Aires | Salute | Prodotti farmaceutici | 231,92 Bln ARS | 14,8x | 0,2 | 34.850 ARS | 0,7% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Amgen AR | Buenos Aires | Salute | Prodotti farmaceutici | 169,38 Bln ARS | 55,1x | -0,92 | 12.850 ARS | 0% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Pfizer DRC | Buenos Aires | Salute | Prodotti farmaceutici | 162,17 Bln ARS | -63,6x | 0,57 | 8.730 ARS | -0,1% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Gilead Sciences | Buenos Aires | Salute | Prodotti farmaceutici | 105,91 Bln ARS | 102,8x | -1,24 | 25.900 ARS | -0,5% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Bristol-Myers Squibb DRC | Buenos Aires | Salute | Prodotti farmaceutici | 105,58 Bln ARS | -16,5x | 0,09 | 21.150 ARS | -0,2% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
GSK plc DRC | Buenos Aires | Salute | Prodotti farmaceutici | 76,74 Bln ARS | 14,8x | -0,2 | 11.600 ARS | -0,6% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Biogen AR | Buenos Aires | Salute | Prodotti farmaceutici | 27,18 Bln ARS | 23,9x | -0,42 | 17.575 ARS | 1% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Cardinal Health | Buenos Aires | Salute | Prodotti farmaceutici | 26,62 Bln ARS | 32,3x | 0,18 | 44.700 ARS | -0,1% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Laboratorios Richmond | Buenos Aires | Salute | Prodotti farmaceutici | 75,91 Mrd ARS | 21,4x | 0,12 | 940 ARS | -1,1% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Inst rosembusc | Buenos Aires | Salute | Prodotti farmaceutici | 4,02 Mrd ARS | 4x | 0,01 | 94,50 ARS | 5% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ |